Earendil Labs Advances HXN-1001 Into Phase IIa Trial
WILMINGTON, Del., April 2, 2026 Earendil Labs, an AI-driven biotechnology company, has announced that the first patient has been...
immunology
Advertisement
Biogen to Acquire Apellis in $5.6B Strategic Pharma Deal
CAMBRIDGE, Mass. & WALTHAM, Mass., USA — March 31, 2026 In a major biopharmaceutical industry consolidation, Biogen Inc. has...
Sanofi Rezurock Wins EU Approval for Chronic GvHD
PARIS, France, March 31, 2026 Sanofi has received European Commission approval for Rezurock® (belumosudil) for the treatment of chronic...
Celldex Barzolvolimab Shows Strong Phase 2 Urticaria Data
Hampton, N.J., USA | March 27, 2026 Celldex Therapeutics reported compelling results from Phase 2 clinical trials of barzolvolimab,...
Novartis Acquires Excellergy in $2B Allergy Innovation Deal
Basel, Switzerland | March 27, 2026 Strategic Acquisition Strengthens Allergy Leadership Novartis has announced a major strategic move to...
Advertisements
Lilly Taltz Zepbound Combo Shows Strong Phase 3b Results
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
Dupixent Approved in Japan for Rare Skin Disease
PARIS, FRANCE & TARRYTOWN, NEW YORK, USA | March 24, 2026 Sanofi and Regeneron have announced that Japan’s Ministry...
Apogee Therapeutics Prices $350M Public Offering
SAN FRANCISCO & BOSTON, USA | March 24, 2026 Apogee Therapeutics, Inc. has successfully announced the pricing of its...
Quotient Therapeutics, Merck Sign $2.2B IBD Deal
CAMBRIDGE, MASSACHUSETTS, March 24, 2026 Quotient Therapeutics has announced a multi-year research collaboration with Merck & Co. to discover...
Harbour BioMed Reports Phase I Success for HBM9378 Antibody
Cambridge, Massachusetts, USA / Rotterdam, Netherlands / Shanghai, China | March 22, 2026 Harbour BioMed has announced the online...
Advertisement
